Cogent Biosciences Inc. announced on July 7, 2025, that it has achieved positive top-line results from Part 2 of the SUMMIT clinical trial for bezuclastinib in patients with non-advanced systemic mastocytosis. These results demonstrate clinically meaningful improvements across primary and secondary endpoints, strengthening the company's plan to submit a new drug application to the U.S. FDA by the end of 2025. The SUMMIT trial results will be detailed at a major medical conference later this year. Additionally, Cogent Biosciences is on track to release top-line results for its ongoing PEAK and APEX trials in the latter half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.